MA52565A - Dérivés de tétrahydro-imidazo[4,5-c]pyridine en tant qu'immunomodulateurs de pd-l1 - Google Patents

Dérivés de tétrahydro-imidazo[4,5-c]pyridine en tant qu'immunomodulateurs de pd-l1

Info

Publication number
MA52565A
MA52565A MA052565A MA52565A MA52565A MA 52565 A MA52565 A MA 52565A MA 052565 A MA052565 A MA 052565A MA 52565 A MA52565 A MA 52565A MA 52565 A MA52565 A MA 52565A
Authority
MA
Morocco
Prior art keywords
immunomodulators
imidazo
tetrahydro
pyridine derivatives
pyridine
Prior art date
Application number
MA052565A
Other languages
English (en)
Other versions
MA52565B1 (fr
Inventor
Liangxing Wu
Kaijiong Xiao
Wenqing Yao
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Priority claimed from PCT/US2019/031728 external-priority patent/WO2019217821A1/fr
Publication of MA52565A publication Critical patent/MA52565A/fr
Publication of MA52565B1 publication Critical patent/MA52565B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA52565A 2018-05-11 2019-05-10 Dérivés de tétrahydro-imidazo[4,5-c]pyridine en tant qu'immunomodulateurs de pd-l1 MA52565B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862670249P 2018-05-11 2018-05-11
PCT/US2019/031728 WO2019217821A1 (fr) 2018-05-11 2019-05-10 Dérivés de tétrahydro-imidazo[4,5-c]pyridine en tant qu'immunomodulateurs de pd-l1

Publications (2)

Publication Number Publication Date
MA52565A true MA52565A (fr) 2021-03-17
MA52565B1 MA52565B1 (fr) 2023-03-31

Family

ID=74446262

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52565A MA52565B1 (fr) 2018-05-11 2019-05-10 Dérivés de tétrahydro-imidazo[4,5-c]pyridine en tant qu'immunomodulateurs de pd-l1

Country Status (2)

Country Link
AR (1) AR115385A1 (fr)
MA (1) MA52565B1 (fr)

Also Published As

Publication number Publication date
MA52565B1 (fr) 2023-03-31
AR115385A1 (es) 2021-01-13

Similar Documents

Publication Publication Date Title
LT3790877T (lt) Tetrahidro-imidazo[4,5-c]piridino dariniai kaip pd-l1 imunomoduliatoriai
MA47120A (fr) Dérivés pyridine utilisés en tant qu'immunomodulateurs
DK3558990T3 (da) Tetrahydroimidazo[4,5-c]pyridinderivater som pd-l1 internaliseringsinducere
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA53675A (fr) Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
EP3784665A4 (fr) Dérivés de pyridazine en tant qu'agents de dégradation de smarca2/4
EP3853220A4 (fr) Dérivés de quinazoline en tant qu'agents antitumoraux
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA45591A (fr) Dérivés de 1,3-dihydroxy-phényle utiles comme immunomodulateurs
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA53881A (fr) Dérivés de pyrido[4,3-d][1,3]oxazin-2-one en tant qu'inhibiteurs de la forme mutée des protéines idh1 et idh2
MA52987A (fr) Dérivés de pyrazolo[1,5-a]pyrazin-4-yl en tant qu'inhibiteurs de jak
MA46264A (fr) Dérivés pyrazolo[1,5-a]pyridine et leur utilisation en tant qu'agents de lutte antiparasitaire
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
EP3533787A4 (fr) Composé de pyridone en tant qu'inhibiteur de c-met
ME03672B (fr) 1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1
MA43021A (fr) Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1
EP3402793A4 (fr) Dérivés de pyridazine en tant qu'activateurs d'eaat2
EP3380475A4 (fr) Dérivés d'octahydropyrrolo [3, 4-c
MA47593A (fr) Dérivés de 1, 4, 6-trisubstitué-2-alkyl-1h-benzo[d]imidazole en tant qu'inhibiteurs de dihydroorotate oxygénase
MA51133A (fr) Dérivés de pyrrole utilisés en tant qu'inhibiteurs d'acc